<DOC>
	<DOCNO>NCT02211014</DOCNO>
	<brief_summary>To characterize safety profile acalabrutinib without dexamethasone subject relapse refractory Multiple Myeloma ( MM )</brief_summary>
	<brief_title>An Open-Label , Phase 1b Study Acalabrutinib With Without Dexamethasone Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Men woman ≥ 18 year age . A confirmed diagnosis MM , relapse , refractory ≥ 1 prior therapy MM , progress time study entry . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use contraception study 30 day last dose study drug sexually active able bear beget child . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism acalabrutinib , put study outcome undue risk Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification Malabsorption syndrome , disease significantly affect gastrointestinal function , gastric bypass , resection stomach small bowel , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Breast feeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>ACP-196</keyword>
	<keyword>acalabrutinib</keyword>
</DOC>